<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font22 { font-size : 22; } .font24 { font-size : 24; } .font26 { font-size : 26; } .font30 { font-size : 30; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font30">the </span>
   <span class="font26">with </span>
   <span class="font24">patients </span>
   <span class="font22">HCC </span>
   <span class="font18">were </span>
   <span class="font17">development </span>
   <span class="font17">for </span>
   <span class="font16">SVR </span>
   <span class="font15">treatment </span>
   <span class="font15">hepatitis </span>
   <span class="font14">was </span>
   <span class="font14">.%, </span>
   <span class="font14">antiviral </span>
   <span class="font14">{background </span>
   <span class="font13">HCV </span>
   <span class="font13">than </span>
   <span class="font13">CHC </span>
   <span class="font13">PEG-IFN/RBV </span>
   <span class="font13">chronic </span>
   <span class="font13">study </span>
   <span class="font13">those </span>
   <span class="font13">rates </span>
   <span class="font13">risk </span>
   <span class="font13">therapy </span>
   <span class="font13">hepatocellular </span>
   <span class="font13">margin </span>
   <span class="font13">not </span>
   <span class="font12">{border-style </span>
   <span class="font12">The </span>
   <span class="font12">cumulative </span>
   <span class="font12">genotype </span>
   <span class="font12">no-treatment </span>
   <span class="font12">plus </span>
   <span class="font12">have </span>
   <span class="font12">new </span>
   <span class="font12">px;} </span>
   <span class="font12">significantly </span>
   <span class="font12">that </span>
   <span class="font12">#ffffff;} </span>
   <span class="font12">(HR </span>
   <span class="font12">ribavirin </span>
   <span class="font12">treated </span>
   <span class="font12">who </span>
   <span class="font12">greater </span>
   <span class="font12">factors </span>
   <span class="font12">group </span>
   <span class="font12">group, </span>
   <span class="font12">(−) </span>
   <span class="font12">age </span>
   <span class="font12">cirrhosis </span>
   <span class="font12">liver </span>
   <span class="font12">rate </span>
   <span class="font12">these </span>
   <span class="font12">without </span>
   <span class="font11">(.%) </span>
   <span class="font11">carcinoma </span>
   <span class="font11">older </span>
   <span class="font11">DAA </span>
   <span class="font11">are </span>
   <span class="font11">presence </span>
   <span class="font11">present </span>
   <span class="font11">(Fig. </span>
   <span class="font11">P &amp;lt; .), </span>
   <span class="font11">higher </span>
   <span class="font11">Hepatol;:–. </span>
   <span class="font11">achieve </span>
   <span class="font11">all </span>
   <span class="font11">been </span>
   <span class="font11">follow-up </span>
   <span class="font11">study, </span>
   <span class="font11">sustained </span>
   <span class="font11">-year </span>
   <span class="font11">active </span>
   <span class="font11">based </span>
   <span class="font11">cirrhosis, </span>
   <span class="font11">other </span>
   <span class="font11">respectively, </span>
   <span class="font11">such </span>
   <span class="font11">(.%, </span>
   <span class="font11">(Table </span>
   <span class="font11">P &amp;lt; .) </span>
   <span class="font11">Study </span>
   <span class="font11">advanced </span>
   <span class="font11">age, </span>
   <span class="font11">developed </span>
   <span class="font11">px; </span>
   <span class="font11">response </span>
   <span class="font11">study. </span>
   <span class="font11">subjects </span>
   <span class="font11">virologic </span>
   <span class="font11">virus </span>
   <span class="font11">{font-family </span>
   <span class="font11">after </span>
   <span class="font11">agents </span>
   <span class="font11">analysis </span>
   <span class="font11">characteristics </span>
   <span class="font11">did </span>
   <span class="font11">drugs </span>
   <span class="font11">effective </span>
   <span class="font11">font-size </span>
   <span class="font11">from </span>
   <span class="font11">genotypes </span>
   <span class="font11">infection </span>
   <span class="font11">infection. </span>
   <span class="font11">median </span>
   <span class="font11">patients, </span>
   <span class="font11">previous </span>
   <span class="font10">(P &amp;lt; .) </span>
   <span class="font10">(n = ) </span>
   <span class="font10">Hepatology;:–. </span>
   <span class="font10">RNA </span>
   <span class="font10">Table </span>
   <span class="font10">as, </span>
   <span class="font10">associated </span>
   <span class="font10">cirrhosis. </span>
   <span class="font10">cirrhotic </span>
   <span class="font10">clinical </span>
   <span class="font10">development. </span>
   <span class="font10">double; </span>
   <span class="font10">effects </span>
   <span class="font10">enrolled </span>
   <span class="font10">found </span>
   <span class="font10">has </span>
   <span class="font10">high </span>
   <span class="font10">highly </span>
   <span class="font10">interferon </span>
   <span class="font10">oral </span>
   <span class="font10">patients. </span>
   <span class="font10">reported </span>
   <span class="font10">side </span>
   <span class="font10">this </span>
   <span class="font10">using </span>
   <span class="font10">(P = .) </span>
   <span class="font10">Although </span>
   <span class="font10">HCV-related </span>
   <span class="font10">However, </span>
   <span class="font10">This </span>
   <span class="font10">anti-HCV </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">considered </span>
   <span class="font10">data </span>
   <span class="font10">era </span>
   <span class="font10">evidence </span>
   <span class="font10">failed </span>
   <span class="font10">incidence </span>
   <span class="font10">independent </span>
   <span class="font10">independently </span>
   <span class="font10">more </span>
   <span class="font10">our </span>
   <span class="font10">peg-interferon </span>
   <span class="font10">predictive </span>
   <span class="font10">recurrence </span>
   <span class="font10">retrospective </span>
   <span class="font10">serum </span>
   <span class="font10">solid; </span>
   <span class="font10">studies </span>
   <span class="font10">therapy. </span>
   <span class="font10">treatment. </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">Figure </span>
   <span class="font10">Inha </span>
   <span class="font10">Liver </span>
   <span class="font10">Med;:–. </span>
   <span class="font10">Median </span>
   <span class="font10">University </span>
   <span class="font10">al.Efficacy </span>
   <span class="font10">allocated </span>
   <span class="font10">because </span>
   <span class="font10">bold </span>
   <span class="font10">can </span>
   <span class="font10">candidates </span>
   <span class="font10">carcinoma, </span>
   <span class="font10">carcinoma: </span>
   <span class="font10">could </span>
   <span class="font10">courier; </span>
   <span class="font10">diagnosis </span>
   <span class="font10">direct-acting </span>
   <span class="font10">duration </span>
   <span class="font10">em; </span>
   <span class="font10">factor </span>
   <span class="font10">long-term </span>
   <span class="font10">lower </span>
   <span class="font10">male </span>
   <span class="font10">may </span>
   <span class="font10">months </span>
   <span class="font10">months. </span>
   <span class="font10">needs </span>
   <span class="font10">patient </span>
   <span class="font10">peginterferon </span>
   <span class="font10">predicted </span>
   <span class="font10">pt;} </span>
   <span class="font10">regimens </span>
   <span class="font10">sofosbuvir </span>
   <span class="font10">subgroups </span>
   <span class="font10">subjects, </span>
   <span class="font10">treatment-naïve </span>
   <span class="font10">weeks </span>
  </p>
 </body>
</html>
